ClinicalTrials.gg
Active, not recruitingNCT06039345Updated Apr 13, 2026

Shoulder RFA Pilot Study

An observational study in Shoulder Pain and Rotator Cuff Injuries, sponsored by University of Utah. Active, not recruiting at 3 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by University of Utah · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
10
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies in Shoulder Pain with a site in United States — 21 open to participants now, 28 under way, none of them phase 3. Shoulder Pain · United States.

Planned enrollment
22nd of 24
10 · median 65
Started
2024
with 5 others
Observational
24 of 146
6 open now
Primary completion
2026-12
later than 9 of 27 live
Registered
125th of 146
by date

Among the 146 studies in Shoulder Pain with a site in United States, this one is the 22nd largest by planned enrollment of the 24 observational ones that give a count, is one of 6 that started in 2024, is one of 24 observational ones, reaches primary completion later than 9 of the 27 other live ones, and was the 125th registered.

Shoulder Pain

738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.

Browse Shoulder Pain studies →

Open to participants now

21 of the 146 studies in Shoulder Pain with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Shoulder Pain with a site in United States, or all of them as a file.
02

Study summary

Through this prospective, single-arm cohort pilot study, we plan to explore the safety and effectiveness of Shoulder Radiofrequency Ablation (SRFA) in patients with non-operative chronic shoulder pain due to shoulder osteoarthritis with or without rotator cuff tears.

Read the detailed description

This will be one of the first collaborative prospective, single-arm cohort using a standardized selection protocol and comprehensive SRFA protocol to treat chronic, refractory shoulder pain due radiographically confirmed glenohumeral joint OA with or without RTC pain, in patients deemed non-surgical candidates by a board-certified orthopedic shoulder surgeon. Upon completing the proposed research, we expect our contribution to fill the knowledge gap on whether SRFA is a potentially viable treatment option for this patient population. This contribution is expected to be substantial because SRFA may be a safe and effective treatment option for many people suffering shoulder pain and debility who are sub-optimal surgical candidates and have historically either been undertreated to have less than ideal treatments options, including opioid-based pain management in particular.

03

Conditions studied

  • Shoulder Pain
  • Rotator Cuff Injuries

Keywords

  • shoulder radiofrequency ablation
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

We will explore the effectiveness of SRFA to reduce chronic shoulder pain in 10 participants who were deemed non-surgical candidates by an orthopedic surgeon and who experienced ≥80% pain relief after a single shoulder joint anesthetic block.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥50 years old capable of understanding and providing consent in English, and capable of complying with the outcome instruments used
  2. ≥3 months of shoulder pain to conventional treatment (i.e., physiotherapy, medication, injections)
  3. Persistent shoulder pain ≥ 4/10 in intensity on a 7-day average
  4. Shoulder pain refractory to conventional treatment (i.e., physical therapy, oral analgesics, steroid injection)
  5. Prior consultation with a board-certified orthopedic shoulder surgeon, deemed a non-surgical candidate for the primary diagnosis of glenohumeral joint pain +/- rotator cuff pain
  6. ≥80% pain relief for at least 30 minutes after a single fluoroscopically-guided block of the sensory branches of the SN, AN, and LPN with 0.5 mL of lidocaine at each nerve
  7. Scheduled for procedure of interest

Exclusion criteria

Exclusion Criteria:

  1. Infection
  2. Allergy to any medication needed to participate in this study
  3. Previous partial/total/reverse shoulder arthroplasty. Participants with a history of RTC repair will not be excluded.
  4. Neurologic disorders including radiculopathy, connective tissue/inflammatory joint disease/widespread soft tissue pain disorder
  5. Severe, uncontrolled psychiatric disorder requiring hospitalization within 6 months
  6. Intraarticular or subacromial injection to the study shoulder within 3 months before C-SRFA
  7. Uncontrolled bleeding diathesis
  8. Pregnancy
  9. Pacemaker, neurostimulator, or other implanted device potentially sensitive to RF energy
  10. Active Worker's compensation claim, litigation, or other possible reason for secondary gain.
  11. Prior shoulder radiofrequency ablation
  12. Daily opioid use
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Numerical Rating Scale (NRS) at 1, 3, 6 and 12 months after the SRFA

    Pain reduction will be measured by calculating the proportion of participants who experienced ≥50% reduction of their shoulder pain on the Numerical Rating Scale (NRS) at 1, 3, 6 and 12 months after the SRFA.

    Time frame: 1, 3, 6 and 12 months

Secondary outcomes

  1. Myotomal strength at 1, 3, 6 and 12 months after SRFA

    We will calculate the proportion of participants who experience a minimal clinically important difference (MCID) in shoulder abduction, elbow flexion, wrist extension, elbow extension and hand grip measured by dynamometer after SRFA. We will do this by calculating the proportion of participants who experience ≥20% change (MCID) in myotomal strength at 1, 3, 6 and 12 months after SRFA.

    Time frame: 1, 3, 6 and 12 months after SRFA

  2. American Shoulder and Elbow Surgeons Score (ASES) at 1,3, 6 and 12 months after SRFA

    We will use the validated American Shoulder and Elbow Surgeons Score (ASES) questionnaire to calculate the proportion of participants who experience an MCID on ASES (defined as a score of ≥ 7) at 1,3, 6 and 12 months after SRFA.

    Time frame: 1, 3, 6 and 12 months after SRFA

  3. Patient Global Impression of Change (PGIC) at 1,3, 6 and 12 months after SRFA

    We will use the validated Patient Global Impression of Change (PGIC) questionnaire to calculate the proportion of participants who experience an MCID on PGIC (defined as a score of ≥ 5) at 1,3, 6 and 12 months after SRFA.

    Time frame: 1, 3, 6 and 12 months after SRFA

07

Study locations

3 sites
08

References and documents

Publications

  • Andersson HI, Ejlertsson G, Leden I, Rosenberg C. Chronic pain in a geographically defined general population: studies of differences in age, gender, social class, and pain localization. Clin J Pain. 1993 Sep;9(3):174-82. doi: 10.1097/00002508-199309000-00004. PubMed 8219517 ↗
  • Chard MD, Hazleman R, Hazleman BL, King RH, Reiss BB. Shoulder disorders in the elderly: a community survey. Arthritis Rheum. 1991 Jun;34(6):766-9. doi: 10.1002/art.1780340619. PubMed 2053923 ↗
  • Allander E. Prevalence, incidence, and remission rates of some common rheumatic diseases or syndromes. Scand J Rheumatol. 1974;3(3):145-53. doi: 10.3109/03009747409097141. No abstract available. PubMed 4428194 ↗
  • Luime JJ, Koes BW, Hendriksen IJ, Burdorf A, Verhagen AP, Miedema HS, Verhaar JA. Prevalence and incidence of shoulder pain in the general population; a systematic review. Scand J Rheumatol. 2004;33(2):73-81. doi: 10.1080/03009740310004667. PubMed 15163107 ↗
  • Virta L, Joranger P, Brox JI, Eriksson R. Costs of shoulder pain and resource use in primary health care: a cost-of-illness study in Sweden. BMC Musculoskelet Disord. 2012 Feb 10;13:17. doi: 10.1186/1471-2474-13-17. PubMed 22325050 ↗
  • Eckmann MS, Bickelhaupt B, Fehl J, Benfield JA, Curley J, Rahimi O, Nagpal AS. Cadaveric Study of the Articular Branches of the Shoulder Joint. Reg Anesth Pain Med. 2017 Sep/Oct;42(5):564-570. doi: 10.1097/AAP.0000000000000652. PubMed 28786899 ↗
  • Eckmann MS, Johal J, Bickelhaupt B, McCormick Z, Abdallah RT, Menzies R, Soliman S, Nagpal AS. Terminal Sensory Articular Nerve Radiofrequency Ablation for the Treatment of Chronic Intractable Shoulder Pain: A Novel Technique and Case Series. Pain Med. 2020 Apr 1;21(4):868-871. doi: 10.1093/pm/pnz335. No abstract available. PubMed 31851366 ↗
  • Bohannon RW. Reference values for extremity muscle strength obtained by hand-held dynamometry from adults aged 20 to 79 years. Arch Phys Med Rehabil. 1997 Jan;78(1):26-32. doi: 10.1016/s0003-9993(97)90005-8. PubMed 9014953 ↗
  • Bohannon RW. Grip strength impairments among older adults receiving physical therapy in a home-care setting. Percept Mot Skills. 2010 Dec;111(3):761-4. doi: 10.2466/03.10.15.PMS.111.6.761-764. PubMed 21319615 ↗
  • Hayes K, Walton JR, Szomor ZL, Murrell GA. Reliability of 3 methods for assessing shoulder strength. J Shoulder Elbow Surg. 2002 Jan-Feb;11(1):33-9. doi: 10.1067/mse.2002.119852. PubMed 11845146 ↗
  • Kolber MJ, Beekhuizen K, Cheng MS, Fiebert IM. The reliability of hand-held dynamometry in measuring isometric strength of the shoulder internal and external rotator musculature using a stabilization device. Physiother Theory Pract. 2007 Mar-Apr;23(2):119-24. doi: 10.1080/09593980701213032. PubMed 17530541 ↗
  • Awatani T, Mori S, Shinohara J, Koshiba H, Nariai M, Tatsumi Y, Nagata A, Morikita I. Same-session and between-day intra-rater reliability of hand-held dynamometer measurements of isometric shoulder extensor strength. J Phys Ther Sci. 2016 Mar;28(3):936-9. doi: 10.1589/jpts.28.936. Epub 2016 Mar 31. PubMed 27134388 ↗
  • Michener LA, McClure PW, Sennett BJ. American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form, patient self-report section: reliability, validity, and responsiveness. J Shoulder Elbow Surg. 2002 Nov-Dec;11(6):587-94. doi: 10.1067/mse.2002.127096. PubMed 12469084 ↗
  • Jones IA, Togashi R, Heckmann N, Vangsness CT Jr. Minimal clinically important difference (MCID) for patient-reported shoulder outcomes. J Shoulder Elbow Surg. 2020 Jul;29(7):1484-1492. doi: 10.1016/j.jse.2019.12.033. Epub 2020 Apr 3. PubMed 32249146 ↗
  • Conger A, Gililland J, Anderson L, Pelt CE, Peters C, McCormick ZL. Genicular Nerve Radiofrequency Ablation for the Treatment of Painful Knee Osteoarthritis: Current Evidence and Future Directions. Pain Med. 2021 Jul 25;22(Suppl 1):S20-S23. doi: 10.1093/pm/pnab129. PubMed 34308957 ↗
  • Conger A, Cushman DM, Walker K, Petersen R, Walega DR, Kendall R, McCormick ZL. A Novel Technical Protocol for Improved Capture of the Genicular Nerves by Radiofrequency Ablation. Pain Med. 2019 Nov 1;20(11):2208-2212. doi: 10.1093/pm/pnz124. PubMed 31131850 ↗
  • Koshi E, Cheney CW, Sperry BP, Conger A, McCormick ZL. Genicular Nerve Radiofrequency Ablation for Chronic Knee Pain Using a Three-Tined Electrode: A Technical Description and Case Series. Pain Med. 2020 Dec 25;21(12):3344-3349. doi: 10.1093/pm/pnaa204. PubMed 32984887 ↗
  • McCormick ZL, Cohen SP, Walega DR, Kohan L. Technical considerations for genicular nerve radiofrequency ablation: optimizing outcomes. Reg Anesth Pain Med. 2021 Jun;46(6):518-523. doi: 10.1136/rapm-2020-102117. Epub 2021 Jan 22. PubMed 33483425 ↗
  • McCormick ZL, Reddy R, Korn M, Dayanim D, Syed RH, Bhave M, Zhukalin M, Choxi S, Ebrahimi A, Kendall MC, McCarthy RJ, Khan D, Nagpal G, Bouffard K, Walega DR. A Prospective Randomized Trial of Prognostic Genicular Nerve Blocks to Determine the Predictive Value for the Outcome of Cooled Radiofrequency Ablation for Chronic Knee Pain Due to Osteoarthritis. Pain Med. 2018 Aug 1;19(8):1628-1638. doi: 10.1093/pm/pnx286. PubMed 29300971 ↗
  • Roberts SL, Stout A, Dreyfuss P. Review of Knee Joint Innervation: Implications for Diagnostic Blocks and Radiofrequency Ablation. Pain Med. 2020 May 1;21(5):922-938. doi: 10.1093/pm/pnz189. PubMed 31407791 ↗
  • Tran A, Reiter DA, Fritz J, Cruz AR, Reimer NB, Lamplot JD, Gonzalez FM. Pilot study for treatment of symptomatic shoulder arthritis utilizing cooled radiofrequency ablation: a novel technique. Skeletal Radiol. 2022 Aug;51(8):1563-1570. doi: 10.1007/s00256-022-03993-y. Epub 2022 Jan 14. PubMed 35029737 ↗
  • Eckmann MS, McCormick ZL, Beal C, Julia J, Cheney CW, Nagpal AS. Putting Our Shoulder to the Wheel: Current Understanding and Gaps in Nerve Ablation for Chronic Shoulder Pain. Pain Med. 2021 Jul 25;22(Suppl 1):S2-S8. doi: 10.1093/pm/pnab152. PubMed 34308959 ↗
  • Bogduk N. On diagnostic blocks for lumbar zygapophysial joint pain. F1000 Med Rep. 2010 Aug 9;2:57. doi: 10.3410/M2-57. PubMed 21173871 ↗
  • Schneider BJ, Joshi M, Ehsanian R, McCormick ZL, Patel J, Zheng P, Nagpal AS. Patient-perceived duration of effect of lidocaine and bupivacaine following diagnostic medial branch blocks; a multicenter study. Interv Pain Med. 2022 Mar 18;1(2):100083. doi: 10.1016/j.inpm.2022.100083. eCollection 2022 Jun. PubMed 39239364 ↗
  • Classifications in Brief: Kellgren-Lawrence Classification of Osteoarthritis - PMC. Accessed June 22, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925407/
  • Diagnosis and treatment of incomplete rotator cuff tears - PubMed. Accessed June 22, 2022. https://pubmed.ncbi.nlm.nih.gov/2182260/

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

Of 49 non-industry observational studies under Shoulder Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 24. This study's planned 34 months is above that.

Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2023
First posted
Sep 15, 2023
StartActual
Feb 7, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06039345
Lead sponsor
University of Utah
Responsible party
Allison Glinka Przybysz (Assistant Professor, University of Utah) — Principal investigator
First posted
Sep 15, 2023
Start date
Feb 7, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion